Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › ivonescimab

ivonescimab

2 published articles · Updated continuously

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Case report on ivonescimab for EGFR-TKI-resistant lung adenocarcinoma with pericardial effusion
Infectious Disease Sys. Review
Case report on ivonescimab for EGFR-TKI-resistant lung adenocarcinoma with pericardial effusion One Drug Shrinks Lung Tumors When Others Stop Working
This is a case report and literature review of a 77-year-old female with EGFR-TKI-resistant advanced lung adenocarcinoma and malignant peric…
A 77-year-old woman with advanced lung cancer saw her tumors shrink and dangerous fluid around her heart disappear after trying a new drug c…
Frontiers May 13, 2026
Ivonescimab Phase II Study Targets 55% DCR in Relapsed Pleural Mesothelioma
Pulmonology & Critical Care Phase II
Ivonescimab Phase II Study Targets 55% DCR in Relapsed Pleural Mesothelioma Could This New Drug Offer Hope for Patients with Returning Pleural Mesothelioma?
A Phase II trial evaluates ivonescimab in 38 pleural mesothelioma patients post-immunotherapy/chemotherapy. The study aims for a ≥55% diseas…
Patients with returning pleural mesothelioma may find hope in ivonescimab, a new drug being tested to control stubborn cancer after standard…
CT.gov Mar 27, 2026